Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKAN NASDAQ:ENSC NASDAQ:ONCT NASDAQ:PALI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$3.66-9.2%$4.03$2.91▼$8.75$1.84M1.59306,346 shs42,300 shsENSCEnsysce Biosciences$2.09-0.5%$2.15$1.62▼$14.67$6.23M1135,312 shs25,416 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.17$1.56M1.1899,758 shsN/APALIPalisade Bio$0.68-0.5%$0.82$0.60▼$4.32$6.20M1.355.27 million shs79,824 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda-9.18%-7.05%-0.32%-2.89%-49.52%ENSCEnsysce Biosciences-0.48%+1.95%+0.48%-4.57%-77.75%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-87.37%PALIPalisade Bio-0.53%-10.37%-36.25%-7.25%-80.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKANAkanda0.8318 of 5 stars0.03.00.00.02.31.70.6ENSCEnsysce Biosciences0.8763 of 5 stars0.04.00.00.04.40.00.0ONCTOncternal TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APALIPalisade Bio2.7154 of 5 stars3.54.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKANAkanda 0.00N/AN/AN/AENSCEnsysce Biosciences 0.00N/AN/AN/AONCTOncternal Therapeutics 2.00Hold$2.00279.79% UpsidePALIPalisade Bio 3.00Buy$12.001,675.67% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKANAkanda$840K2.00N/AN/A$9.37 per share0.39ENSCEnsysce Biosciences$5.21M1.19N/AN/A$1.03 per share2.03ONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05PALIPalisade BioN/AN/AN/AN/A$0.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKANAkanda-$4.10MN/A0.00∞N/AN/AN/AN/AN/AENSCEnsysce Biosciences-$7.99M-$4.03N/AN/AN/A-88.76%-167.23%-104.59%11/11/2025 (Estimated)ONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/APALIPalisade Bio-$14.44M-$4.06N/AN/AN/AN/A-214.94%-135.09%11/11/2025 (Estimated)Latest ONCT, AKAN, PALI, and ENSC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ENSCEnsysce Biosciences-$1.02-$0.79+$0.23-$0.79$0.67 million$1.37 million8/11/2025Q2 2025PALIPalisade Bio-$0.48-$0.58-$0.10-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKANAkandaN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKANAkandaN/A1.391.39ENSCEnsysce BiosciencesN/A2.102.10ONCTOncternal TherapeuticsN/A2.392.39PALIPalisade BioN/A1.621.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKANAkanda1.00%ENSCEnsysce Biosciences5.63%ONCTOncternal Therapeutics16.05%PALIPalisade Bio11.79%Insider OwnershipCompanyInsider OwnershipAKANAkanda20.39%ENSCEnsysce Biosciences7.90%ONCTOncternal Therapeutics11.20%PALIPalisade Bio0.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKANAkanda110460,000364,000Not OptionableENSCEnsysce Biosciences102.97 million2.73 millionNot OptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataPALIPalisade Bio109.12 million9.06 millionNot OptionableONCT, AKAN, PALI, and ENSC HeadlinesRecent News About These CompaniesPalisade Bio releases virtual KOL Connect segment on PALI-2108August 25, 2025 | msn.comPalisade Bio Features Dr. Brian Feagan in Discussion on Fibrostenotic Crohn's Disease and Innovations in IBD Treatment with PALI-2108August 25, 2025 | quiverquant.comQPalisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108August 25, 2025 | globenewswire.comPalisade Bio files to sell 8.9M shares of common stock for holdersAugust 16, 2025 | msn.comPalisade reports outcomes from Phase Ib ulcerative colitis studyAugust 11, 2025 | finance.yahoo.comPalisade Bio’s PALI-2108: A Promising New Treatment for Ulcerative ColitisAugust 8, 2025 | msn.comPalisade Bio Reports Positive Phase 1b Data for PALI-2108 in Ulcerative Colitis Demonstrating Safety and EfficacyAugust 7, 2025 | quiverquant.comQPalisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108August 7, 2025 | globenewswire.comPalisade Bio’s locally-activated, terminal ileum and colon-targeted PDE4 B/D inhibitor, PALI-2108 receives Chinese patentAugust 4, 2025 | pharmabiz.comPPalisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in ChinaJuly 31, 2025 | globenewswire.comPalisade Bio’s Phase 1 Study on PALI-2108: A New Hope for Ulcerative Colitis TreatmentJuly 30, 2025 | tipranks.comPalisade Bio, Inc. Announces Agreement to Exercise Existing Warrants and Raise Approximately $3.9 MillionJuly 23, 2025 | quiverquant.comQPalisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comPalisade Bio Announces Exercise of Previously Issued Warrants for $3.9 MillionJuly 23, 2025 | finance.yahoo.comPalisade Bio Announces Exercise of Previously Issued Warrants for $3.9 MillionJuly 23, 2025 | globenewswire.comPalisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comPalisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of ...July 11, 2025 | morningstar.comMPalisade Bio, Inc. Appoints Dr. Emil Chuang to Board of ... - NasdaqJuly 11, 2025 | nasdaq.comPalisade Bio appoints to its Board of DirectorsJuly 9, 2025 | msn.comPalisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of DirectorsJuly 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCT, AKAN, PALI, and ENSC Company DescriptionsAkanda NASDAQ:AKAN$3.66 -0.37 (-9.18%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.71 +0.05 (+1.26%) As of 08/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.Ensysce Biosciences NASDAQ:ENSC$2.09 -0.01 (-0.48%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.12 +0.03 (+1.63%) As of 08/29/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Oncternal Therapeutics NASDAQ:ONCTOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Palisade Bio NASDAQ:PALI$0.68 0.00 (-0.53%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$0.67 -0.01 (-1.15%) As of 08/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
